All In Biotech

Drug Trial Radar · NCT07769242

A Phase I/II Clinical Trials of SHR-8203 Injection in Participants With Advanced Solid Tumors

An Open-label, Multi-center Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SHR-8203 Injection in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 22, 2026

Primary completion

Dec 30, 2029

Study completion Dec 30, 2029

Sponsor

Sponsor type
Industry
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a multicenter, open-label Phase I/II clinical study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and efficacy of SHR-8203 injection in participants with advanced solid tumors.

Conditions

  • Solid Tumors

Interventions

  • SHR-8203 InjectionDrug

    SHR-8203 injection, in Dose 1/ Dose 2/ Dose 3/ Dose 4.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of subjects with dose-limiting toxicity (DLT)Time frame: From first dose of study treatment until the end of Cycle 1(up to 21 days)
  2. Incidence and severity of adverse events (AEs)Time frame: From the first visit to the end of the safety follow-up period (1 year)
  3. Maximum Tolerated Dose (MTD)Time frame: During the DLT observation period, the dose level at which the estimated toxicity probability was closest to the target toxicity probability (i.e., 0.3) (up to 21 days)
  4. Determination of Recommended Phase II dose (RP2D)Time frame: After dose optimization, sufficient safety, tolerability, PK and preliminary efficacy results were obtained, and the dose selected for the subsequent indication expansion stage was confirmed by SRC discussion (1 year).
  5. Objective Response Rate (ORR)Time frame: From time of first dose of SHR-8203 until the date of objective disease progression or death (1 year)

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Macquarie University Clinical Trials Unit

    Macquarie Park, New South Wales, Australia · Not yet recruiting

  • Scientia Clinical Research Ltd

    Randwick, New South Wales, Australia · Not yet recruiting

  • ICON Cancer Centre South Brisbane

    South Brisbane, Queensland, Australia · Not yet recruiting

  • Southern Oncology Clinical Research Unit (SOCRU)

    Bedford Park, South Australia, Australia · Not yet recruiting

  • St John of God Subiaco Hospital

    Subiaco, Western Australia, Australia · Not yet recruiting

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.